一项关于脂质体两性霉素B治疗艾滋病患者隐球菌性脑膜炎的疗效及安全性的回顾性研究。

A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.

作者信息

Torre D, Banfi G, Tambini R, Speranza F, Zeroli C, Martegani R, Airoldi M, Fiori G

机构信息

Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy.

出版信息

J Infect. 1998 Jul;37(1):36-8. doi: 10.1016/s0163-4453(98)90389-9.

DOI:10.1016/s0163-4453(98)90389-9

PMID:9733375

Abstract

To evaluate the efficacy and safety of Amphotericin B dissolved in dextrose (Amb) or in a lipid emulsion (Intralipid, Amb-IL) in AIDS patients with cryptococcal meningitis, we conducted a retrospective study in 30 AIDS patients with cryptococcal meningitis. A clinical complete resolution was obtained in 11 patients (55%) treated with Amb, and in six patients (60%) treated with Amb-IL. Intralipid did not decrease the infusion-related adverse effects, in particular nephrotoxicity and anaemia. Our results indicate that Amb-IL formulation is useful in the treatment of cryptococcal meningitis in AIDS patients, but it does not reduce the infusion-related adverse events.

摘要

为评估溶解于葡萄糖溶液中的两性霉素B（Amb）或脂质乳剂（英脱利匹特，Amb-IL）治疗艾滋病合并隐球菌性脑膜炎患者的疗效和安全性，我们对30例艾滋病合并隐球菌性脑膜炎患者进行了一项回顾性研究。接受Amb治疗的11例患者（55%）和接受Amb-IL治疗的6例患者（60%）实现了临床完全缓解。英脱利匹特并未降低输注相关不良反应，尤其是肾毒性和贫血。我们的结果表明，Amb-IL制剂可用于治疗艾滋病患者的隐球菌性脑膜炎，但不能减少输注相关不良事件。